SK Bioscience has received approval from the Human Research Ethics Committee in Australia for a phase I/II trial of its mRNA-based Japanese encephalitis vaccine candidate, GBP-560.
Cyrus Biotechnology Inc. has reported data on its engineered IdeS (IgG-degrading enzyme of S. pyogenes) protease for IgG-driven autoimmune disease, showing potent activity on repeat doses in a rabbit redosing model while eliciting no anti-drug antibodies.
Researchers from the University of Connecticut have worked in the development of a collection of propargyl-linked antifolate (PLA) chemotypes for infectious pathogens with different functionalities, including potential anti-cancer, anti-inflammatory and anti-infection activities.
Seismic Therapeutic Inc. has provided preclinical data for S-4321, a novel dual-cell bidirectional (DcB) PD-1:FcγRIIb antibody being developed for the treatment of autoimmune disease.
Ventus Therapeutics US Inc. patents describe new cyclic GMP-AMP synthase (MB21D1; cGAS) inhibitors potentially useful for the treatment of autoimmune disease, rheumatic diseases and liver diseases, among others.
Scientists from Recludix Pharma Inc. presented the preclinical characterization of REX-7117, an orally available, reversible, SH2 domain-targeting STAT3 inhibitor, being developed for the treatment of inflammatory diseases.
Kyverna Therapeutics Inc. has presented details on the development and preclinical characterization of KYV-102, an autologous fully human anti-CD19 CAR T-cell therapy developed for diseases driven by B cells, such as systemic lupus erythematosus (SLE), among others.
RSS
